



9 April 2008

Companies Announcements Office
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

BioPharmica (ASX: BPH) ASX Release

BIOPHARMICA AND GE HEALTHCARE

Molecular Discovery Systems (MDSystems) a wholly owned subsidiary of Perth biotech company BioPharmica Limited (BPH) has successfully completed a Collaborative Research Agreement with GE Healthcare, one of the world's largest healthcare companies.

The imaging of cancer patient tissue samples using BioPharmica's GE InCell Analyzer clearly demonstrated the effectiveness of this imaging platform and provided valuable insight into future image analysis strategies. With the conclusion of this project and the increasing requirement to apply the InCell Analyzer to cell based screening protocols for the BioPharmica/UWA HLS5 project the showcase status of the MDSystem's facility was also concluded by mutual agreement.

The development of cell based imaging assays has proved to be the most strategically significant aspect of the collaboration and the area in which BioPharmica will concentrate going forwards. The three phases of this collaboration were:

- | | |
|---------|--|
| Phase 1 | the provision of existing sensors to compliment existing target assays; |
| Phase 2 | the development of specific tools/reagents for the target HLS5; and |
| Phase 3 | utilizing these tools/assays to evaluate effects on molecular signaling. |

All three phases were completed successfully resulting in validation data for GE Healthcare and new screens and constructs for use within BioPharmica for studying the regulatory role and interactions of HLS5. Biopharmica will continue to develop these technologies to support the future work on HLS5 and the high throughput screening of this target against potential drug leads.

Dr. Christopher Norey from GE Healthcare stated that “the collaboration agreement had been completed to the mutual satisfaction of both parties” and commented that there are also “interesting areas for future consideration”.

It was also stated GE Healthcare is committed to ensure BioPharmica has the tools required to make the best use of the InCell Analyzer 1000 and Investigator analysis packages along with the various reagent offerings.

There is a desire within both parties to explore possible avenues of further collaboration in the future.

Yours Faithfully,



David Breeze
Executive Director

About BioPharmica

BioPharmica (ASX: BPH) is an Australian Stock Exchange listed company developing biomedical research with academic and hospital institutes. The Company provides early stage funding for a direct collaboration, a spin out company or to secure a license. BioPharmica provides product development, funding and commercial strategies, whilst the institutional partner provides a majority of the infrastructure and research expertise.

About GE Healthcare

GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. GE Healthcare’s expertise in medical imaging and information technologies, medical diagnostics, patient monitoring and life support systems, disease research, drug discovery, and biopharmaceutical manufacturing technologies is helping physicians detect disease earlier and to tailor personalized treatments for patients. GE Healthcare offers a broad range of products and services that are improving productivity in healthcare and enhancing patient care by enabling healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions. GE Healthcare is a \$15 billion unit of General Electric Company (NYSE: GE) headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 43,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com